Connected Drug Delivery Devices Market by Type of Device (Connected / Smart Wearable Injectors, Connected / Smart Inhalers, Connected / Smart Pen Injectors, Connected / Smart Autoinjectors and Connected / Smart Needle-free Injection Systems), Mode of Conn

Connected Drug Delivery Devices Market by Type of Device (Connected / Smart Wearable Injectors, Connected / Smart Inhalers, Connected / Smart Pen Injectors, Connected / Smart Autoinjectors and Connected / Smart Needle-free Injection Systems), Mode of Connectivity (Bluetooth-enabled Devices, Near Field Communication-enabled Devices, Cellular-enabled Devices and Wide Area Network-enabled Devices), Route of Administration (Parenteral and Inhalational), Therapeutic Area (Metabolic Disorders, Respiratory Disorders, Autoimmune Disorders and Other Disorders), and Geographical Regions ((North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and Rest of the Europe), Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Israel, Saudi Arabia, and Rest of the Middle East and North Africa), and Latin America and Rest of the World (Brazil, Argentina and Rest of the World)): Industry Trends and Global Forecasts, Till 2035

CONNECTED DRUG DELIVERY DEVICES MARKET: OVERVIEW

As per Roots Analysis, the global connected drug delivery devices market is estimated to grow from USD 4.4 billion in the current year to USD 12.7 billion by 2035, at a CAGR of 10.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Device

Connected / Smart Wearable Injectors

Connected / Smart Inhalers

Connected / Smart Pen Injectors

Connected / Smart Autoinjectors

Connected / Smart Needle-free Injection Systems

Mode of Connectivity

Bluetooth-enabled Devices

Near Field Communication-enabled Devices

Cellular-enabled Devices

Wide Area Network-enabled Devices

Route of Administration

Parenteral

Inhalational

Therapeutic Area

Metabolic Disorders

Respiratory Disorders

Autoimmune Disorders

Other Disorders

Key Geographical Regions

North America (US and Canada)

Europe (UK, Germany, France, Italy, Spain and Rest of the Europe)

Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific)

Middle East and North Africa (Egypt, Israel, Argentina and Rest of the Middle East and North Africa)

Latin America and Rest of the World (Brazil, Argentina and Rest of the World)

CONNECTED DRUG DELIVERY DEVICES MARKET: GROWTH AND TRENDS

Currently, a significant proportion of the global healthcare burden is being attributed to non-adherence to the medication that is prescribed to patients. Poor medication adherence is one of the leading causes of discrepancies between results obtained from randomized clinical studies and real-world health data (captured outside clinical settings). According to the World Health Organization (WHO), two-thirds of the population is prescribed at least one medication. Of these, an estimated 50% of the patients do not follow the treatment regimen as prescribed by the doctors. Some of the factors that have influenced non-adherence amongst the patient population include challenges linked to accessing medications and healthcare services, and the inability to understand complex dosing schedules.

Over the years, several strategies have been developed by various pharmaceutical companies and healthcare providers to improve patient compliance towards their treatment regimens. One such alternative that has gained popularity in the last few years is connected / smart drug delivery devices and other digital health solutions that enable patients / healthcare providers to track the medication activity of patients and thereby, help improve drug adherence. Notably, the integration of connected / smart drug delivery devices with emerging technologies, such as artificial intelligence and blockchain can further enhance the prospects for these devices. With the growing demand for accurate and effective digital health solutions and advancement in technologies (integration with telehealth platforms), the global connected drug delivery devices market is poised to witness steady growth, in the foreseen future.

CONNECTED DRUG DELIVERY DEVICES MARKET: KEY INSIGHTS

The report delves into the current state of the connected drug delivery devices market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 85 connected / smart drug delivery devices have been launched / approved or are currently under development; notably, the market landscape features the presence of both established players and new entrants.

2. Smart wearable injectors emerged as the most prominent connected drug delivery device; further, majority of these devices are intended for the administration of medications via subcutaneous route.

3. At present, 30 innovative add-on sensors are available / under development for integration with conventional drug delivery devices; most of the add-on sensor manufacturers are start-ups based in Europe.

4. Close to 50% of the add-on sensors are compatible with inhalers; of these, more than 55% can support all three features, namely audio / visual alerts, bluetooth connectivity and companion mobile application.

5. In pursuit of gaining a competitive edge, stakeholders are actively enhancing their existing capabilities by improving their respective product portfolios and complying to the evolving industry standards.

6. Several clinical trials have been registered related to connected / smart drug delivery devices, across different geographies.

7. More than 25% of the deals related to connected / smart drug delivery devices were inked in the last three years; majority of the intercontinental deals were signed by players based in North America.

8. Several investors have realized the opportunity within the domain by investing multi-billion dollars in the past few years; further, majority of the amount was raised by players based in North America.

9. By analyzing the key drivers and barriers affecting the evolution of connected drug delivery devices market, valuable insights can be generated regarding current and future opportunities within this domain.

10. Owing to the ability of connected drug delivery devices to provide precise dosing and remote patient monitoring, the market is anticipated to witness an annualized growth of 10.1% over the next decade.

CONNECTED DRUG DELIVERY DEVICES MARKET: KEY SEGMENTS

Currently, Connected / Smart Wearable Injectors Segment Holds the Maximum Share of the Connected Drug Delivery Devices Market

Based on the type of device, the market is segmented into connected / smart wearable injectors, connected / smart inhalers, connected / smart pen injectors, connected / smart autoinjectors and connected / smart needle-free injection systems. It is worth highlighting that the current connected drug delivery devices market is dominated by connected / smart wearable injectors. This trend is likely to remain the same in the near future. This can be attributed to the growing prevalence of chronic conditions and the continuous efforts of stakeholders to develop advanced devices.

Connected Drug Delivery Devices Supporting Bluetooth are Likely to Dominate the Connected Drug Delivery Devices Market During the Forecast Period

Based on the mode of connectivity, the market is segmented into Bluetooth-enabled devices, near field communication-enabled devices, cellular-enabled devices, and wide area network-enabled devices. The current market is expected to be driven by connected drug delivery devices supporting Bluetooth and a similar trend is anticipated in the long term. This can be attributed to the widespread adoption of Bluetooth connectivity due to its easy setup process, absence of any need for additional equipment and universal availability on smartphones. Additionally, the reliability and established presence of Bluetooth technology in the market make it a trusted choice for patients seeking connectivity solutions.

Inhalational Route is the Fastest Growing Segment of the Connected Drug Delivery Devices Market During the Forecast Period

Based on the route of administration, the market is segmented into parenteral and inhalational. It is anticipated that the devices delivering drugs via inhalational route are likely to grow at a higher CAGR during the forecast period. This can be attributed to the fact that administration of drugs via inhalational route is flexible, painless, and offers sustained localized action.

Metabolic Disorders Segment Accounts for the Largest Share of the Connected Drug Delivery Devices Market

Based on the therapeutic area, the market is segmented into metabolic disorders, respiratory disorders, autoimmune disorders and other disorders. While metabolic disorders account for a relatively higher market share, it is worth highlighting that the autoimmune disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. Majority share is expected to be captured by North America and Europe. It is worth highlighting that over the years, the market for Asia-Pacific is expected to grow at a higher CAGR. This can be attributed to the growing research and development activity for novel drug delivery solutions, the increasing number of biopharmaceutical start-ups and the upcoming device approvals in the region.

Example Players in the Connected Drug Delivery Devices Market

Bigfoot Biomedical

BIOCORP

Eitan Medical

E3D Elcam Drug Delivery Device

EoFlow

Gerresheimer

Insulet

Medtronic

Medtrum

Nemera

Phillips-Medisize

Roche

Sonceboz

SOOIL Development

Tandem Diabetes Care

West Pharmaceutical Services

Ypsomed

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Senior Director, Global Strategic Marketing, Medical, Phillips-Medisize

Co-founder and Chief Executive Officer, Cognita Labs

Founder and Chief Executive Officer, Portal Instruments

Chief Executive Officer and President, Enable Injections

Chief Executive Officer, Amiko

Vice President and Chief Scientist, Elcam Medical

Director (Global Communications) and Graham Reynolds, Former Vice President (Strategic Partnerships and Business Development), West Pharmaceutical Services

Former Chief Executive Officer, Avoset Health (acquired by Eitan Medical)

Former Director (Front-end Innovation and Head of Connected Health), Phillips-Medisize

Former Vice President (Marketing and Alliance Management), Sorrel Medical (acquired by LTS lohmann therapie-systeme)

Advisor (Strategy and Business Development), etectRx

CONNECTED DRUG DELIVERY DEVICES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the connected drug delivery devices market, focusing on key market segments, including [A] type of device, [B] mode of connectivity, [C] route of administration, [D] therapeutic area and [E] key geographical regions.

Market Landscape (Connected / Smart Drug Delivery Devices): A comprehensive evaluation of integrated connected drug delivery devices, considering various parameters, such as [A] stage of development, [B] launch year of device, [C] type of integrated device, [D] route of administration, [E] therapeutic area, [F] target indication, [G] key features, [H] mode of connectivity, [I] availability of companion mobile application and [J] availability of data storage / cloud platform. In addition, it also includes tabulated information on regulatory approvals, geographical reach and drugs compatible with connected / smart drug delivery devices. Further, the chapter provides a detailed list of companies engaged in manufacturing connected drug delivery devices, along with detailed analysis based on various parameters, such as [K] year of establishment, [L] company size (in terms of employee count), [M] location of headquarters and [N] most active players (in terms of the number of integrated connected drug delivery devices manufactured).

Market Landscape (Add-on Sensors): A comprehensive evaluation of add-on sensors, considering various parameters, such as [A] stage of development, [B] launch year of device, [C] compatible device, [D] route of administration, [E] therapeutic area, [F] target indication, [G] key features, [H] mode of connectivity, [I] availability of companion mobile application and [J] availability of data storage / cloud platform. It also includes detailed information on regulatory approvals, geographical reach and drugs that can be delivered using add-on sensors (in combination with conventional drug delivery devices). In addition, it provides a detailed list of companies engaged in manufacturing add-on sensors for drug delivery devices, along with detailed analysis based on various parameters, such as [K] year of establishment, [L] company size (in terms of employee count), [M] location of headquarters and [N] most active players (in terms of the number of add-on sensors manufactured).

Product Competitiveness Analysis: A comprehensive competitive analysis of connected drug delivery devices and add-on sensors, examining factors, such as manufacturer strength and portfolio strength.

Company Profiles: In-depth profiles of key connected drug delivery device providers, based in North America, Europe and Asia-Pacific, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio, [D] recent developments, and [F] an informed future outlook.

Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various connected drug delivery devices based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of device, [F] type of sponsor / collaborator, [G] therapeutic area, [H] study design, [I] leading industry players (based on number of clinical trials), [J] leading connected / smart drug delivery devices (based on number of clinical trials) and [K] geography.

Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2020, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] class of device, [D] type of integrated device, [E] compatible device [F] most active players (in terms of number of partnerships signed) and [G] regional distribution.

Funding and Investment Analysis: A detailed evaluation of the investments made in the connected drug delivery devices domain, based on several parameters, such as [A] year of funding, amount invested (USD million), [B] type of funding, [C] class of device, [D] geography, [E] most active players (in terms of number of funding instances and amount raised), and [F] most active investors (in terms of number of funding instances).

Value Chain Analysis: A comprehensive value chain analysis that explores the various stages involved in the development of connected or smart drug delivery devices. This includes a discussion on research and development (R&D), product manufacturing and assembly, distribution, marketing and sales, and post-market surveillance, as well as details on the cost requirements at each of these stages.

Case Study: Detailed case studies on two most common indications (namely asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.

Regulatory Landscape: A discussion on general regulatory guidelines issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.

SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry’s evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What factors are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

10% Free Content Customization

Detailed Report Walkthrough Session with Research Team

Free Updated report if the report is 6-12 months old or older